XML 33 R5.htm IDEA: XBRL DOCUMENT v3.20.1
STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)
Common Stock
Additional Paid-in Capital
Retained Deficit
Total
Balance at Feb. 28, 2018 $ 131,449 $ 120,146,481 $ (120,385,630) $ (107,700)
Balance (in shares) at Feb. 28, 2018 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   477,718   477,718
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   1,081,051   1,081,051
Net loss     (1,637,717) (1,637,717)
Balance at Feb. 28, 2019 $ 131,449 121,705,250 (122,023,347) (186,648)
Balance (in shares) at Feb. 28, 2019 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   529,568   529,568
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   1,138,975   1,138,975
Net loss     (1,634,482) (1,634,482)
Balance at Feb. 29, 2020 $ 131,449 $ 123,373,793 $ (123,657,829) $ (152,587)
Balance (in shares) at Feb. 29, 2020 131,448,444